Search

Your search keyword '"Kolstad, Arne"' showing total 713 results

Search Constraints

Start Over You searched for: Author "Kolstad, Arne" Remove constraint Author: "Kolstad, Arne"
713 results on '"Kolstad, Arne"'

Search Results

1. Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

3. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

6. Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma

10. T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes

12. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

14. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 - a Nordic Lymphoma Group study

15. Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

16. A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma

21. POSTER: CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)

22. CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)

23. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 – a Nordic Lymphoma Group study

26. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

28. Figure S1-S8 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma

29. Supplementary Tables S1-S2 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma

30. Data from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma

31. Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established high-risk factors

32. Exploring new prognostic biomarkers in Mantle Cell Lymphoma:a comparison of the circSCORE and the MCL35 score

33. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

38. Supplementary table S1 from T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling

39. Supplementary methods and references, Supplementary Figures 1-9 from T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling

40. Supplementary figures 1-9 from T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling

41. Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score.

44. Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors

45. Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

46. Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

47. Exploring New Prognostic Biomarkers in Mantle Cell Lymphoma: The Best RNA Based Risk Score

48. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

49. IBCL-271 Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up

50. Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow- Up

Catalog

Books, media, physical & digital resources